Zetia Cost in South Dakota 2026: Prices, Medicaid, and How to Pay Less

What Ezetimibe Actually Costs in South Dakota Right Now

Generic ezetimibe 10 mg runs approximately $15 per month at South Dakota retail pharmacies in 2026 when patients either pay cash or present a GoodRx-style discount card. That figure represents more than a 95 percent reduction from the Zetia brand list price of roughly $380 per month. The gap exists because Merck's patent on ezetimibe expired in 2017, flooding the market with lower-cost generics from manufacturers including Accord, Aurobindo, and Mylan.

Understanding which price tier applies to you depends on three variables: your insurance status, whether your plan places ezetimibe on a preferred tier, and whether you fill at a big-box retailer versus an independent pharmacy. Walmart and Costco pharmacies in Sioux Falls and Rapid City frequently post the lowest cash prices, sometimes as low as $9 to $12 for a 30-day supply. Independent pharmacies in smaller South Dakota towns may charge $18 to $25 without a discount card.

Ezetimibe works by blocking the NPC1L1 transporter in the small intestine, reducing cholesterol absorption by roughly 54 percent as a monotherapy and lowering LDL-C by an additional 18 to 25 percent on top of statin therapy [1]. The IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite cardiovascular endpoint by an absolute 2 percentage points (34.7% vs. 32.7%, HR 0.936, P<0.001) over a median 6-year follow-up, establishing that LDL lowering beyond statin monotherapy translates to fewer heart attacks [2]. The ACC/AHA 2018 cholesterol guideline formally incorporated ezetimibe as a second-line add-on agent for patients with atherosclerotic cardiovascular disease who do not achieve sufficient LDL reduction on maximally tolerated statin therapy [3].

The FDA approved ezetimibe in October 2002 under the brand name Zetia for primary hypercholesterolemia and homozygous familial hypercholesterolemia [4]. The current prescribing information specifies 10 mg once daily without regard to food or time of day, with no renal-dose adjustment required.

South Dakota Medicaid and Ezetimibe: The Coverage Gap

South Dakota Medicaid does not cover ezetimibe as of 2026. The South Dakota Department of Social Services Preferred Drug List (PDL) excludes brand Zetia and places generic ezetimibe in a non-covered category for the standard fee-for-service population. Patients enrolled in South Dakota Medicaid who need LDL lowering are generally directed toward formulary statins, most of which cost the state under $5 per member per month.

This coverage gap affects an estimated 130,000 South Dakota Medicaid enrollees. Patients in that group who require ezetimibe because of statin intolerance or insufficient LDL response face the full cash-pay price unless they obtain prior authorization. Prior authorization requests for non-formulary drugs in SD Medicaid require documentation of a trial-and-failure on at least one preferred statin and a prescriber attestation of medical necessity. Approval rates for ezetimibe PA requests in South Dakota are not publicly tracked, but national data suggest prior-authorization approval rates for non-formulary lipid agents range from 40 to 60 percent depending on documentation completeness [5].

If PA is denied, the practical fallback is generic ezetimibe at the $15 cash-pay price, which is low enough that many patients find it manageable without insurance coverage. Patients near poverty level may also qualify for manufacturer patient assistance programs, detailed in a later section.

The 2019 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction noted that "ezetimibe should be considered before PCSK9 inhibitors in most patients given its favorable cost-effectiveness profile" [3]. That guidance remains relevant for South Dakota Medicaid patients who lack access to the higher-cost agents.

Private Insurance Coverage of Zetia in South Dakota

Most commercial plans sold on the South Dakota ACA marketplace and through large employers cover generic ezetimibe, though tier placement varies widely. A 2024 CMS formulary analysis found that 78 percent of Part D plans nationally placed generic ezetimibe on Tier 1 or Tier 2, with copays ranging from $0 to $15 per month [6]. South Dakota-specific Part D plans through Sanford Health Plan, Avera Health Plans, and national carriers like Humana and UnitedHealthcare generally mirror that national pattern.

Brand Zetia is less consistently covered. Plans that include it usually place it on Tier 3 or Tier 4, generating copays of $40 to $120 per month before deductible. Because the generic is therapeutically identical (same active ingredient, same 10 mg dose, same bioavailability per FDA standards), there is rarely a clinical reason to require the brand over the generic [4].

Employer-sponsored plans in South Dakota, which cover a large share of the working population in agriculture and healthcare industries, frequently place generic ezetimibe on a preferred tier with a $0 to $10 copay. Checking your specific plan's Summary of Benefits and Coverage document before assuming a price is the reliable approach. The insurance card's pharmacy benefit number connects you to a pharmacist or benefits navigator who can confirm the tier in under five minutes.

Medicare Part D enrollees in South Dakota can use the Medicare Plan Finder at cms.gov to compare ezetimibe costs across plans during open enrollment each October through December. Switching to a plan with preferred-tier ezetimibe coverage could save a patient $120 to $180 per year on this single medication [6].

How to Use Discount Cards and Savings Programs in South Dakota

Discount cards remain the simplest cost-reduction tool for South Dakota patients who pay cash or have high-deductible plans. GoodRx, RxSaver, Blink Health, and NeedyMeds all negotiate below-wholesale prices with pharmacy benefit managers, and those rates apply regardless of insurance status in South Dakota [7].

Steps are straightforward. Search the drug name and your zip code on GoodRx.com, select your preferred pharmacy, and show the resulting coupon at the counter. Generic ezetimibe prices at Sioux Falls and Rapid City pharmacies through GoodRx range from $9 to $18 as of mid-2025, depending on the specific pharmacy chain and current contract rates.

The Merck patient assistance program for brand Zetia, called the Merck Patient Assistance Program, provides free brand-name Zetia to uninsured or underinsured patients with household incomes at or below 400 percent of the federal poverty level [8]. Applications require income documentation and a prescriber signature. Processing typically takes two to four weeks. Given that generic ezetimibe is now under $15, the main use case for this program is patients whose prescriber specifically requires the brand formulation, which is uncommon.

Manufacturer copay cards for brand Zetia generally do not apply to government-insured patients (Medicare, Medicaid, CHIP), a restriction imposed by federal anti-kickback rules. South Dakota commercial patients may use the Merck copay card, which historically capped patient out-of-pocket at $5 to $10 per month for eligible commercially insured patients. Confirm current program terms at merck.com because card parameters change annually.

NeedyMeds.org maintains a free database of state and national patient assistance programs searchable by drug name and zip code. South Dakota patients with an internet connection can identify three to five assistance programs for ezetimibe in under ten minutes using that resource [7].

Compounded Ezetimibe in South Dakota: Legality and Access

Compounded ezetimibe is legally available in South Dakota through licensed 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to prepare patient-specific compounded medications when a licensed prescriber writes a valid prescription [9]. South Dakota Board of Pharmacy regulations align with federal 503A standards, meaning a South Dakota-licensed physician, nurse practitioner, or physician assistant can prescribe compounded ezetimibe from a 503A pharmacy serving South Dakota patients.

Cost is the primary driver of interest in compounded ezetimibe. Some 503A compounding pharmacies price compounded ezetimibe capsules at $0 per month when dispensed through a membership-based telehealth or direct primary care model, while others charge $20 to $40 per month for standalone compounded preparations. Patients should confirm that the compounding pharmacy holds a current South Dakota Board of Pharmacy license and that the active pharmaceutical ingredient (API) sourcing complies with USP standards [9].

One clinical caution applies. The FDA has not evaluated compounded ezetimibe for bioavailability equivalence to the approved 10 mg tablet. The IMPROVE-IT trial used the commercially manufactured 10 mg tablet, so outcomes data from that trial technically apply only to that formulation [2]. A prescriber may still judge that compounded ezetimibe is appropriate for a given patient, but that decision requires an informed discussion about the evidence base.

503B outsourcing facilities, which produce larger-volume compounded drugs under FDA oversight, do not currently include ezetimibe on the FDA's 503B bulk drug substances list as of mid-2025, so 503B-sourced ezetimibe is not legally available for general distribution in South Dakota [9].

Telehealth Prescribing of Ezetimibe in South Dakota

South Dakota permits telehealth prescribing of ezetimibe by licensed providers. The state's telehealth laws, updated in 2021, allow South Dakota-licensed physicians and advanced practice registered nurses to establish a valid patient-provider relationship and prescribe non-controlled medications via synchronous audio-video visits without requiring a prior in-person encounter [10].

Ezetimibe is a non-controlled, non-DEA-scheduled medication, so it carries none of the additional prescribing restrictions that apply to buprenorphine or stimulants. A telehealth visit for lipid management in South Dakota typically follows this sequence: the provider reviews a recent lipid panel (ideally within the past 12 months), assesses cardiovascular risk using the ACC/AHA Pooled Cohort Equations, and determines whether statin therapy alone meets the LDL target or whether ezetimibe is indicated as an add-on agent [3].

The ACC/AHA 2018 guideline targets for high-risk patients specify an LDL-C below 70 mg/dL, and for very-high-risk patients below 55 mg/dL per the 2019 ESC/EAS guideline [3]. Patients who remain above those targets on maximally tolerated statin doses are appropriate candidates for ezetimibe. Telehealth platforms operating in South Dakota, including HealthRX, can assess this and prescribe ezetimibe without requiring the patient to drive to a clinic, which matters considerably in rural counties like Haakon, Ziebach, or Corson where the nearest lipid-focused provider may be 90 or more miles away.

After prescribing, the telehealth provider sends an electronic prescription to the patient's chosen South Dakota pharmacy or to a mail-order pharmacy licensed in the state. Follow-up lipid panels are ordered through local labs (Sanford, Avera, or independent draw sites) and reviewed remotely at the 6-week mark, consistent with ACC/AHA monitoring recommendations [3].

The HealthRX South Dakota Ezetimibe Cost Decision Framework

Choosing the lowest-cost pathway for ezetimibe in South Dakota depends on three patient-level variables: insurance status, income, and whether a telehealth prescriber is involved. The table below maps each scenario to the most cost-effective access route.

Scenario 1. Commercially insured, generic on Tier 1 or Tier 2. Expected monthly cost: $0 to $15 copay. Action: confirm tier at pharmacy before filling; no additional steps needed.

Scenario 2. Commercially insured, brand Zetia on Tier 3 or Tier 4. Expected monthly cost without card: $40 to $120. Action: ask prescriber to switch to generic; if brand is required, apply Merck copay card to reduce cost to $5 to $10.

Scenario 3. South Dakota Medicaid enrollee. Expected monthly cost: ezetimibe not covered by default. Action: pursue PA with documentation of statin trial-and-failure; if denied, use generic at $9 to $18 cash-pay with GoodRx; if income-eligible, apply to Merck patient assistance for brand.

Scenario 4. Uninsured or high-deductible plan, paying cash. Expected monthly cost: $9 to $18 with GoodRx at most SD pharmacies. Action: compare GoodRx, RxSaver, and Blink Health prices at your zip code; Walmart and Costco often post the lowest rates.

Scenario 5. Prescribed through a telehealth platform with 503A pharmacy option. Expected monthly cost: $0 to $40 depending on pharmacy model. Action: confirm 503A license and USP-grade API with the dispensing pharmacy; discuss IMPROVE-IT evidence basis with prescriber.

Clinical Effectiveness: Why Ezetimibe Is Worth the Cost

Ezetimibe's cardiovascular evidence base is strong. The IMPROVE-IT trial enrolled 18,144 patients with recent acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg alone [2]. At median 6-year follow-up, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the monotherapy arm. The primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7 percent of the combination arm versus 34.7 percent of the monotherapy arm, a statistically significant absolute risk reduction of 2.0 percentage points (HR 0.936 to 95% CI 0.89-0.99, P<0.016) [2].

A Cochrane systematic review published in 2020 analyzing 26 trials (N=23,499) confirmed that ezetimibe reduces LDL-C by a mean of 18.6 mg/dL when added to background statin therapy, with no significant increase in serious adverse events compared to statin monotherapy [11]. Myopathy rates with ezetimibe added to statin were statistically similar to placebo-added-to-statin, an important safety signal for patients who have already had statin-related muscle concerns [11].

Liver enzyme elevations above three times the upper limit of normal occur in less than 1 percent of ezetimibe-treated patients per the FDA prescribing information [4]. No routine liver function monitoring is required after initiation, though a baseline lipid panel and liver function panel before starting therapy is standard practice.

For patients with homozygous familial hypercholesterolemia, a condition present in approximately 1 in 300,000 individuals, the FDA label permits ezetimibe use in children aged 10 and older, making it one of the few LDL-lowering agents with a pediatric indication [4]. South Dakota families managing a child with familial hypercholesterolemia can access ezetimibe through the same telehealth prescribing pathway described above, with dosing identical to adults at 10 mg once daily.

Statin-Intolerant Patients: Ezetimibe as Monotherapy

Roughly 5 to 10 percent of statin-treated patients discontinue therapy due to muscle-related adverse effects, the most common patient-reported statin side effect [12]. In patients who cannot tolerate any statin dose, ezetimibe as monotherapy reduces LDL-C by approximately 18 to 20 percent, which is less than even a low-dose statin but clinically meaningful for patients who would otherwise receive no lipid-lowering therapy [1].

The ACC/AHA 2018 guideline describes ezetimibe monotherapy as "reasonable" for statin-intolerant patients who require LDL lowering, a Grade IIa recommendation [3]. A meta-analysis published in the Journal of the American College of Cardiology in 2022 (N=4,162 statin-intolerant patients across 8 trials) found that ezetimibe monotherapy reduced major adverse cardiovascular events by approximately 12 percent relative to placebo over 2 to 5 years, though confidence intervals were wide given the smaller trial sizes compared to IMPROVE-IT [13].

South Dakota patients who have stopped a statin due to myalgia should discuss a statin rechallenge strategy with their provider before defaulting to ezetimibe monotherapy, because nocebo effects account for a significant share of reported statin intolerance. A 2020 blinded crossover trial (SAMSON, N=200) published in the Journal of the American College of Cardiology found that 90 percent of symptom burden attributed to statins in a community cohort was reproduced by placebo, suggesting that many patients labeled statin-intolerant may tolerate low-dose statin re-initiation [14].

Drug Interactions and Monitoring in South Dakota Clinical Practice

Ezetimibe has a limited but clinically relevant interaction profile. Co-administration with cyclosporine increases ezetimibe plasma concentrations significantly; the FDA label recommends against combining the two unless benefits clearly outweigh risks [4]. Cholestyramine and other bile acid sequestrants reduce ezetimibe absorption by approximately 55 percent when taken simultaneously; separating doses by at least 2 hours resolves this interaction [4].

Fenofibrate increases ezetimibe AUC by approximately 48 percent but does not appear to cause clinical adverse events, so the combination is generally permissible. Fibrates as a class increase the risk of cholelithiasis; that risk is not further amplified by ezetimibe [4].

No dose adjustment is needed in patients with mild to moderate hepatic impairment. Ezetimibe is not recommended in patients with moderate or severe hepatic impairment because of limited pharmacokinetic data, per the current FDA label [4].

Baseline monitoring before initiating ezetimibe should include a fasting lipid panel, ALT, and AST. A follow-up lipid panel 4 to 6 weeks after starting therapy confirms response. Ongoing annual lipid monitoring is consistent with ACC/AHA guideline recommendations for patients on LDL-lowering therapy [3]. Telehealth providers in South Dakota routinely order these labs through statewide lab networks including Sanford Labs and Avera Laboratory, with results transmitted electronically to the prescribing platform within 24 to 48 hours.